BAY 59-7939
Atrial Fibrillation
BayerPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Atrial Fibrillation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Edoxaban National Taiwan University Hospital | Phase 4 | A |
Rivaroxaban VA Office of Research and Development | Phase 4 | BBB |
Dabigatran Pfizer | Phase 4 | BBB |
Apixaban Regeneron Pharmaceuticals | Phase 4 | BBB |
WARFARIN Pfizer | Phase 4 | BBB |
View all 40 →
Same molecule, other indications
BAY 59-7939 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →